SCHEMBL6080290

SCHEMBL6080290

N#Cc1cc(-c2ccccc2)cc2c(O)cc(C(=O)O)nc12

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 3/20 0.40
XDH P47989 3/20 0.39
ALDH1A1 P00352 2/20 0.38
F11 P03951 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
KDM5B Q9UGL1 1/20 0.37
SCN9A Q15858 1/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079541 0.87 ALDH1A1 (0.40) MCL1ALDH1A1NPSR1TDP1KDM4E
SCHEMBL6080470 0.83 KDM4E (0.43) XDHF11TDP1KDM4ESCN9A
SCHEMBL6080080 0.83 MCL1 (0.46) MCL1ALDH1A1TDP1KDM4E
SCHEMBL31353161 0.81 ALDH1A1 (0.41) MCL1XDHALDH1A1F11NPSR1
SCHEMBL6080460 0.81 XDH (0.38) XDHALDH1A1KDM4E
SCHEMBL6080939 0.80 GPR35 (0.34) MCL1XDHALDH1A1F11TDP1
SCHEMBL6080738 0.80 MCL1 (0.43) MCL1ALDH1A1KDM4EHPGD
SCHEMBL6591404 0.77 GPR35 (0.35) XDHF11TDP1KDM4E
SCHEMBL6595262 0.76 ALOX15 (0.51) MCL1ALDH1A1KDM4E
SCHEMBL10215355 0.76 LDHA (0.45) MCL1KDM4EESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
EP-1451159-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2004-09-01 EP claimed
WO-2003010146-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2003-02-06 WO claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed
EP-1451159-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2004-09-01 EP disclosed
WO-2003010146-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL MCL1 998/4885XDH 128/4885ALDH1A1 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.